January 21, 2021 Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer
August 26, 2020 Trishula Therapeutics Established to Advance Novel TTX-030, and Anti-CD39 Antibody, Being Evaluated in Phase 1/1B Study in Advanced Cancers
info@trishulatx.com 1-650-509-5732
